Updated on 11 June 2015
Eisai Co. Ltd., a leading global research and development-based pharmaceutical company headquartered in Japan, has launched Lenvima (lenvatinib) in the United Kingdom.
Lenvima is a treatment option for people with radioactive iodine refractory differentiated thyroid cancer (RAI refractory DTC). Advanced thyroid cancer is a difficult to treat condition with a poor prognosis and lenvatinib represents a significant step forward for patients in the UK.
Lenvatinib is indicated for the treatment of adult patients with progressive locally advanced or metastatic, differentiated (papillary, follicular, Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).
Lenvatinib, discovered and developed by Eisai, is an oral molecular tri-specific targeted therapy that possesses a potent selectivity and a binding mode different to other tyrosine kinase inhibitors (TKI). Lenvatinib simultaneously inhibits the activities of several different molecules including vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFR), RET, KIT and platelet-derived growth factor receptors (PDGFR).
This potentially makes lenvatinib the first TKI that simultaneously inhibits the kinase activities of FGFR 1-4 as well as VEGFR 1-3. In addition, lenvatinib was found to have a new Type V binding mode of kinase inhibition that is distinct from existing compounds.